In the present study of patients with psoriasis, 4-month treatment with the inhibitor of PDE4, apremilast, improved endothelial glycocalyx barrier function, as assessed by PBR5–25 μm, and microvascular perfusion, as estimated by functional microvascular density. Here, PDE4A is linked to psoriasis.